Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Research analysts at Seaport Res Ptn lowered their Q3 2025 EPS estimates for shares of Curaleaf in a report released on Monday, August 11th. Seaport Res Ptn analyst S. Randhawa now expects that the company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.07). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Seaport Res Ptn also issued estimates for Curaleaf's Q4 2025 earnings at ($0.08) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%.
Separately, Cormark upgraded shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a research report on Friday, August 8th.
View Our Latest Research Report on CURLF
Curaleaf Stock Down 1.4%
CURLF stock opened at $2.72 on Wednesday. Curaleaf has a one year low of $0.68 and a one year high of $3.58. The stock has a market capitalization of $1.82 billion, a PE ratio of -8.50 and a beta of 0.69. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.70 and a current ratio of 1.47. The company has a fifty day moving average of $1.15 and a 200-day moving average of $1.07.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.